12:00 AM
 | 
Mar 31, 2014
 |  BioCentury  |  Emerging Company Profile

Indi Molecular: Building better binders

Indi's synthetic PCCs mimic antibody affinity and specificity, add versatility

Indi Molecular Inc.'s protein-catalyzed capture platform produces synthetic peptides that could be used as in vivo imaging agents and in vitro diagnostics when low target immunogenicity or suboptimal pharmacokinetics limit the utility of mAbs.

Despite their limitations, mAbs are still the platform of choice for protein recognition tasks because peptide-based approaches do not consistently yield agents with antibody-like affinity and specificity.

Indi's protein-catalyzed capture (PCC) agents mimic the binding specificity and affinity of mAbs but have biochemical properties similar to small molecules: they are more stable, easier to manufacture and can access a wider range of targets.

"We've been able to create a completely synthetic approach to building binding molecules," said CEO Albert Luderer.

Luderer is also CEO of Integrated Diagnostics Inc., which develops blood-based proteomic tests to detect early stage disease. Integrated spun Indi out so the parent company could raise a B round without obligating its investors to support the two different technologies.

To create a PCC agent, Indi screens...

Read the full 798 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >